CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(06): 605-617
DOI: 10.1055/a-0887-0285
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

Article in several languages: English | deutsch
Andreas Schneeweiss
1  Nationales Centrum für Tumorerkrankungen (NCT), Universitätsklinikum, Heidelberg, Germany
2  Deutsches Krebsforschungszentrum, Heidelberg, Germany
Carsten Denkert
3  Institut für Pathologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg, Marburg, Germany
Peter A. Fasching
4  Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
Carlo Fremd
1  Nationales Centrum für Tumorerkrankungen (NCT), Universitätsklinikum, Heidelberg, Germany
Oleg Gluz
5  Brustzentrum Niederrhein, Evangelisches Krankenhaus Bethesda, Mönchengladbach, Germany
6  Westdeutsche Studiengruppe, Mönchengladbach, Germany
Cornelia Kolberg-Liedtke
7  Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
Sibylle Loibl
8  German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany
9  Zentrum für Hämatologie und Onkologie Bethanien, Goethe Universität Frankfurt, Frankfurt am Main, Germany
Hans-Joachim Lück
10  Gynäkologie Onkologie, Gynäkologisch-onkologische Praxis, Hannover, Germany
› Author Affiliations
Further Information

Publication History

received 23 January 2019
revised 29 March 2019

accepted 01 April 2019

Publication Date:
14 June 2019 (online)


The rapid increase in knowledge in tumour biology and tumour pathogenesis of triple-negative breast cancer (TNBC) has resulted in new therapeutic approaches and new therapeutic concepts for treatment. For years, TNBC has been considered to be a difficult-to-treat tumour due to its generally aggressive tumour biology and in view of limited therapeutic options. The risk of recurrence and metastasis is higher than in the case of other breast cancer subtypes of the same stage. In addition to surgery and radiation in the curative situation, systemic chemotherapy with anthracyclines and/or taxanes is still the therapy of choice. New therapeutic approaches are based on the knowledge that TNBC is a molecularly very heterogeneous disease. Research groups are working to classify TNBC better and better on a molecular level and use this molecular subtyping as the basis for new therapeutic strategies. The most promising new approaches and considerations regarding the therapy of TNBCs are shown below. In addition, the current therapeutic strategies are discussed using a fictitious case history, taking the current data and the resultant therapeutic consequence into account.